The American Journal of Medicine
Volume 123, Issue 3, Supplement , Pages S19-S27 , March 2010

Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function

  • Sunder Mudaliar, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Sunder Mudaliar, MD, VA San Diego Healthcare System (Mail Code: 111G), 3350 La Jolla Village Drive, San Diego, California 92161
    • ,
  • Robert R. Henry, MD

References 

  1. National Diabetes Information Clearinghouse. National Diabetes Statistics. 2007;[NDIC Website.] http://diabetes.niddk.nih.gov/DM/PUBS/statistics/Accessed August 4, 2009
  2. International Diabetes Federation. Diabetes Prevalence. 2007;[International Diabetes Federation Website.] http://www.diabetesatlas.org/content/some-285-million-people-worldwide-will-live-diabetes-2010Accessed January 15, 2010
  3. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165
  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  5. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes (A progressive disease). Diabetes. 1995;44:1249–1258
  6. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab. 1976;42:222–229
  7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110
  8. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes. Diabetes Care. 2004;27:2585–2589
  9. American Diabetes Association. Diabetes prevention hopes revived for thiazolidinedione. [news release] San Francisco, CA: American Diabetes Association Annual Meeting; June 12, 2008;http://www.medpagetoday.com/MeetingCoverage/ADA/9784Accessed November 3, 2009
  10. Nauck MA, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52
  11. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;9:301–307
  12. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397–4408
  13. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830
  14. Drucker , Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  15. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991–5997
  16. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762–768
  17. Nauck MA, Frid A, Hermansen K, et al. LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care. 2009;32:84–90
  18. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics. Br J Pharmacol. 2003;140:123–132
  19. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic β-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008;25:152–156
  20. Lee YS, Shin S, Shigihara T, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes. 2007;56:1671–1679
  21. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43:173–181
  22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  23. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293:E1289–E1295
  24. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide–1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209–E1215
  25. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36–52
  26. The effect of liraglutide on the endothelial function in subjects with type 2 diabetes mellitus. http://clinicaltrials.gov/ct2/show/NCT00620282?intr=%22Glimepride%22Accessed August 4, 2009
  27. The vascular effects of exenatide versus metformin in patients with pre-diabetes. http://clinicaltrials.gov/ct2/show/NCT00546728Accessed August 4, 2009. ClinicalTrials.gov identifier NCT00546728.
  28. Mullin MP, Koska J, Schwartz EA, Schwenke DC, Reaven PD. Acute administration of exenatide improves endothelial function following a high-fat meal. Diabetes. 2009;58(suppl 1):A173;Abstract 640-P
  29. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide–1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965
  30. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide–1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824–829
  31. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide–1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694–699
  32. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146:243–249
  33. The effect of exenatide compared to insulin glargine on cardiac function and metabolism in type 2 diabetic patients with congestive heart failure (NYHA II): a randomized comparator-controlled trial. http://clinicaltrials.gov/ct2/show/NCT00766857?term=exenatide+AND+myocardial&rank=2Accessed August 4, 2009
  34. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22:1137–1143
  35. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448–1460
  36. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–2635
  37. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–1100
  38. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275–286
  39. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608–1610
  40. Colagiuri S, Frid A, Zdravkovic M, Duyen Le-Thi T, Vaag A. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Diabetes. 2008;57(suppl 1):A164–A165Abstract 554-P
  41. Madsbad S. Liraglutide effect and action in diabetes (LEAD™) trial. Expert Rev Endocrinol Metab. 2009;4:119–129
  42. Yamamoto H, Kishi T, Lee CE, et al. Glucagon-like peptide–1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide–1 with central autonomic control sites. J Neurosci. 2003;23:2939–2946
  43. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091
  44. Zinman B, Hoogwerf BJ, Duran-Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477–485
  45. Kim D, MacConell I, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487–1493
  46. Drucker DJ, Buse JB, Taylor K, et al. DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250
  47. Bergenstal RM, Kim T, Trautmann M, Zhuang D, Okerson T, Taylor K. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes. Circulation. 2008;118:S1086;Abstract 1239
  48. Garber A, Henry R, Ratner R, et al. LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481
  49. Marre M, Shaw J, Brandle M, et al. LEAD-1 SU Study Group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–278
  50. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–1230
  51. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. Diabetes. 2008;57:A159–A160Abstract 536-P
  52. Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47
  53. Jin CH, Chae SY, Son S, et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release. 2009;133:172–177

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 This work was supported by the Department of Veterans Affairs, VA San Diego Healthcare System, San Diego, California.

PII: S0002-9343(09)01077-8

doi: 10.1016/j.amjmed.2009.12.006

The American Journal of Medicine
Volume 123, Issue 3, Supplement , Pages S19-S27 , March 2010

Article Tools

* Image Usage & Resolution